DNA Repair Enzymes and Cytotoxic Effects of Temozolomide: Comparative Studies Between Tumor Cells and Normal Cells of the Immune System

References

• Ames BN, Gold LS. Endogenous mutagens and the causes of aging and cancer. Mutat Res 1991; 250: 3–16.
   PubMed Web of Science ®Google Scholar
• Simic MG. DNA markers of oxidative processes in vivo: relevance to carcinogenesis and anticarcinogenesis. Cancer Res 1994; 54 (suppl.): 1918s-1923s.
   Google Scholar
• Gerson BL. Clinical relevance of MGMT in the treat-ment of cancer. J Clin Oncol 2002; 20: 2388–2399.
   PubMed Web of Science ®Google Scholar
• Pegg AE. Mammalian 06-alkylguanine - DNA alkyltrans-ferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990; 50: 6119-6129.
   Google Scholar
• Scudiero DA, Meyer SA, Clatterbuck BE, Mattern MR, Ziolkowski CHJ, Day RS. Sensitivity of human cell strains hav-ing different abilities to repair 06-methylguanine in DNA to inactivation by alkylating agents including chloroethylni-trosourea. Cancer Res 1984; 44: 2467-2474.
   Google Scholar
• Yarosh DB. The role of 06-methylguanine-DNA methyl-transferase in cell survival, mutagenesis and carcinogenesis. Mutat Res 1985; 145: 1–16.
   PubMed Web of Science ®Google Scholar
• Tentori L, Graziani G, Gilbert' S, Lacal PM, Bonmassar E, D'Atri S. Triazene compounds induce apoptosis in 06-alkyl-guanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia 1995; 9: 1888-1895.
   Google Scholar
• D'Atri S, Piccioni D, Castellano A, et al. Chemosensitivity to triazene compounds and 06-alkylguanine DNA alkyltransferase levels: Studies with blast of leukaemic patients. Ann Oncol 1995; 6: 389–393.
   PubMed Web of Science ®Google Scholar
• Tentori L, Orlando L, Lacal PM, et al. Inhibition of 06-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) poly-merase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol Pharmacol 1997; 52: 249–258.
   PubMed Web of Science ®Google Scholar
• Jiricny J. and Nystrom-Lahti M. Mismatch repair defects in cancer. Curr Opin Genet Dev 2000; 10: 157–161.
   PubMed Web of Science ®Google Scholar
• Modrich P. Strand-specific mismatch repair in mam-malian cells. J Biol Chem 1997; 272: 24727–24730.
   PubMed Web of Science ®Google Scholar
• Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogene-sis. Mutat Res 2002; 511: 145–178.
   PubMed Web of Science ®Google Scholar
• Hussein MR, Wood GS. Building bridges in cancer: mismatch repair and microsatellite instability. Am J Dermatopathol 2002; 24: 76–81.
   PubMed Web of Science ®Google Scholar
• Haydon AM, Jass JR. Emerging pathways in colorec-tal-cancer development. Lancet Oncol 2002; 3: 83–88.
   PubMed Web of Science ®Google Scholar
• Jass JR, Walsh MD, Barker M, Simms LA, Young J, Leggett BA. Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability. Eur J Cancer 2002; 38 (7): 858–866.
   PubMed Web of Science ®Google Scholar
• Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, Modrich P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 1993; 90: 6424–6428.
   PubMed Web of Science ®Google Scholar
• Koi M, Umar A, Chauhan DP, et al. Human chromo-some 3 corrects mismatch repair deficiency and microsatellite instability and reduce N-methyl-N'-nitro-N-nitrosoguanidine tol-erance in colon tumor cells with homozygous hMLH1 muta-tion. Cancer Res 1994; 54: 4308-4312.
   Google Scholar
• Carethers JM, Hawn MT, Chauhan DP, et al. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanide. J Clin Invest 1996; 98: 199–206.
   PubMed Web of Science ®Google Scholar
• D'Atri S, Tentori L, Lacal PM, et al. Involvement of the mismatch repair system in temozolomide-induced apopto-sis. Mol Pharmacol 1998; 54: 334–341.
   PubMed Web of Science ®Google Scholar
• Aquilina G, Zijno A, Moscufo N, Dogliotti E, Bignami M. Tolerance to methylnitrosourea-induced DNA damage is associated with 6-thioguanine resistance in CHO cells. Carcinogenesis 1989; 10: 1219-1223.
   Google Scholar
• Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273: 1109–1111.
   PubMed Web of Science ®Google Scholar
• Drummond JT, Anthoney A, Brown R, Modrich P. Cisplatin and adriamycin resistance are associated with MutL and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996; 271: 19645–19648.
   PubMed Web of Science ®Google Scholar
• Anthoney DA, MacIlwrath AJ, Gallagher WM, Edlin ARM, Brown R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res 1996; 56: 1374-1381.
   Google Scholar
• McClay EF, Mastrangelo MJ. Systemic chemotherapy for malignant melanoma. Semin Oncol 1988; 15: 569–577.
   PubMed Web of Science ®Google Scholar
• Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-car-bamoyl -3-methyl-imidazo 5,1-d-1, 2, 3, 5-tetrazin - 4 (3H) - one (CCRG 81045; M&B 39831) a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47: 5846-5852.
   Google Scholar
• Woll PJ, Crowther D, Johnson PWM, et al. Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. Br J Cancer 1995; 72: 183–184.
   PubMed Web of Science ®Google Scholar
• Bleehen NM, Newlands ES, Lee SM, et al. Cancer Research Campaign phase II trial of temozolomide in metasta-tic melanoma. J Clin Oncol 1995; 13: 910–913.
   PubMed Web of Science ®Google Scholar
• Bower M, Newlands ES, Bleehen NM, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997; 40: 484–488.
   PubMed Web of Science ®Google Scholar
• Danson SJ, Middleton MR. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther 2001; 1: 13–19.
   PubMedGoogle Scholar
• O'Reilly SM, Newlands ES, Glaser MG, et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumors. Eur J Cancer 1993; 29A: 940–942.
   PubMed Web of Science ®Google Scholar
• Giampietri A, Bonmassar E. Drug-induced modulation of immune responses in mice, effect of 5-(3,3-dimethyl 1 tri azeno)-imidazole-4-carboxamide (DTIC), and cyclo-phos-phamide (Cy). J Immunopharmacol 1978; 1: 61–65.
   PubMedGoogle Scholar
• Nardelli B, Puccetti P, Romani L, Sava G, Bonmassar E, Fioretti MC. Chemical xenogenization of murine lymphoma cells with triazene derivatives: immunotoxicological studies. Cancer Immunol Immunother 1984; 17: 213–217.
   PubMed Web of Science ®Google Scholar
• Alvino E, Pepponi R, Pagani E, et al. 06-Benzylguanine enhances the in vitro immunotoxic activity of Temozolomide on natural or antigen-dependent immunity J Pharmacol Exp Ther 1999; 291: 1292-1300.
   Google Scholar
• Porcelli SA. The CD1 system: antigen-presenting mole-cules for T cell recognition of lipids and glycolipids. Ann Rev Immunol 1999; 17: 297–329.
   PubMed Web of Science ®Google Scholar
• Skopek TR, Liber HL, Penman BW and Thilly WG. Isolation of a human lymphoblastoid line heterozygous at the thymidine kinase locus: Possibility for a rapid human cell mutation assay. Biochem Biophys Res Commun 1978; 84: 411–416.
   PubMed Web of Science ®Google Scholar
• Goldmacher VS, Cuzick RA, Thilly WG. Isolation and partial characterization of human cell mutants differing in sen-sitivity to killing and mutation by methylnitrosourea and N-methyl-N'-nitro-N-nitrosoguanidine. J Biol Chem 1986; 261: 12462–12471.
   PubMedGoogle Scholar
• Papadopoulos N, Nicolaides NC, Liu B, “et al.”. Mutation of GTBP in genetically unstable cells. Science 1995; 268: 1915–1917.
   Google Scholar
• Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989; 119: 203–210.
   PubMed Web of Science ®Google Scholar
• Morten JEN, and Margison GP. Increased 06-alkylgua-nine alkyltransferase activity in Chinese hamster V79 cells fol-lowing selection with chloroethylating agents. Carcinogenesis 1988; 9: 45–49.
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for quanti-tation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976; 72: 248–254.
   PubMed Web of Science ®Google Scholar
• D'Atri S, Romani L, Bonmassar E, et al. Untreated or drug-treated tumor cells are differentially recognized by allo-geneic lymphocytes. Int J Immunopharmaco 1994; 16: 569–579.
   PubMed Web of Science ®Google Scholar
• D'Incalci M, Citti L, Taverna P, Catapano CV. Importance of DNA repair enzyme 06-alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev 1988; 15: 279–292.
   PubMed Web of Science ®Google Scholar
• Zlotogorski C, Erickson LC. Pretreatment of human colon tumor cells with DNA methylating agents inhibits their ability to repair chloroethyl monoadducts. Carcinogenesis 1984; 5: 83–87.
   PubMed Web of Science ®Google Scholar
• Lee SM, Thatcher N, Margison GP. 06-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res 1991; 51: 619–623.
   PubMed Web of Science ®Google Scholar
• Panella TJ, Smith DC, Schold SC, et al. Modulation of 06-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: A phase I trial. Cancer Res 1992; 2: 2456-2459.
   Google Scholar
• Lee SM, Margison GP, Woodcock AA, Thatcher N. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer 1993; 67: 1356–1360.
   PubMed Web of Science ®Google Scholar
• Aamadal S, Gerard B, Bohman T, D'Incalci M. Sequential administration of dacarbazine and fotemustine in patient with disseminated malignant melanoma: An effective combination with unexpected toxicity. Eur J Cancer 1992; 213: 447–450.
   Google Scholar
• Dolan ME, Pegg A. 06-benzylguanine and its role in chemotherapy. Clin Cancer Res 1997; 3: 837–847.
   PubMed Web of Science ®Google Scholar
• Long L, Dolan ME. Role of cytochrome P450 isoen-zymes in metabolism of 0(6)-benzylguanine: implications for dacarbazine activation. Clin Cancer Res 2001; 7: 4239–4244.
   PubMed Web of Science ®Google Scholar
• Hobin DA, Fairbairn II. Genetic chemoprotection with mutant 06-alkylguanine-DNA-alkyltransferases. Curr Gene Ther 2002, 2: 1–8.
   PubMedGoogle Scholar
• Galloway SM, Greenwood SK, Hill RS, Bradt CI, Bean CL. A role for mismatch repair in production of chromosome aberrations by methylating agents in human cells. Mutat Res 1995; 346: 231–245.
   PubMed Web of Science ®Google Scholar
• Karran P, Bignami M. Self-destruction and tolerance in resistance of mammalian cells to alkylation damage. Nucleic Acids Res 1992; 20: 2933–2940.
   PubMed Web of Science ®Google Scholar
• Franchi A, Papa G, D'Atri S, Piccioni D, Masi M, Bonmassar E. Cytotoxic effects of dacarbazine in patients with acute myelogenous leukaemia: a pilot study. Haematologica 1992; 77: 146–150.
   PubMed Web of Science ®Google Scholar
• Giuliani, A, Tentori L, Pepponi R, et al. Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: influence of 3'-azido-3'-deoxythymidine. Pharmacol Res 1997; 35: 135–140.
   PubMed Web of Science ®Google Scholar
• Porcelli SA. The CD1 family: a third lineage of antigen-presenting molecules. Adv Immunol 1995; 59: 1–98.
   PubMed Web of Science ®Google Scholar
• Porcelli SA, Segelke BW, Sugita M, Wilson IA, Brenner MB. The CD1 family of lipid antigen-presenting molecules. Immunol Today 1998; 19: 362–368.
   PubMedGoogle Scholar
• Moody DB, Besra GS. Glycolipid targets of CD1-medi-ated T-cell responses. Immunology 2001; 104: 243–251.
   PubMed Web of Science ®Google Scholar
• Bonmassar E, Bonmassar A, Vadlamudi S, Goldin A. Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide. Cancer Res 1972; 32: 1450-1466.
   Google Scholar
• Bonmassar E, Bonmassar A, Vadlamudi S, Goldin A. Immunological alteration of leukemic cells in vivo after treat-ment with an antitumor drug. Proc Natl Acad Sci USA 1970; 66: 1089–1095.
   PubMed Web of Science ®Google Scholar
• Fioretti MC, Bianchi R, Romani L, Bonmassar E. Drug-induced immunogenic changes of murine leukemia cells: disso-ciation of onset of resistance and emergence of novel immunogenicity. J Natl Cancer Inst 1983; 71: 1247–1251.
   PubMed Web of Science ®Google Scholar
• Graziani G, Faraoni I, Grohmann U, et al. 06-alkylgua-nine-DNA alkyltransferase attenuates triazene-induced cytotoxi-city and tumor cell immunogenicity in murine L1210 leukemia. Cancer Res 1995; 55: 6231-6236.
   Google Scholar
• Nardelli B, Puccetti P, Romani L, Sava G, Bonmassar E, Fioretti MC. Chemical xenogenization of murine lymphoma cells with triazene derivatives: immunotoxicological studies. Cancer Immunol Immunother 1984; 17: 213–217.
   PubMed Web of Science ®Google Scholar